CRISPR gene therapies should be widely adopted as a standard treatment option for sickle cell disease

What's this about?

People disagree about whether CRISPR gene therapy should become a usual treatment for all people with sickle cell disease.

Casgevy is a CRISPR treatment that changes a person's own stem cells to help their blood work better.

What supporters say

• Casgevy cut severe pain attacks for most people in its main study.
• It raised fetal hemoglobin, a blood protein that helps red cells keep a safer shape.
• Many people said they had less pain and felt better in daily life.
• People do not need a matched donor because doctors use their own stem cells.
• Using a person's own cells also avoids a major transplant risk called graft-versus-host disease.

What critics say

• Studies show the clearest gains for people with severe and repeat pain attacks.
• We do not know yet if these gains will last for a whole life.
• The FDA, the US drug safety group, allows Casgevy only for ages 12 and up with repeat severe attacks.
• The study results do not yet show that every person with sickle cell disease will benefit.

The bottom line

CRISPR therapy can bring very large short-term gains for some people with severe sickle cell disease.

It should help selected people, but we do not have enough proof to make it the usual choice for everyone yet.

CRISPR gene therapy has opened a new chapter in treating sickle cell disease, offering some patients the prospect of long periods without debilitating pain crises. But the evidence supports it most strongly as a treatment for selected patients with severe disease, not yet as a universal standard for everyone with the condition.

The case for

The leading CRISPR treatment, exagamglogene autotemcel, known as exa-cel or Casgevy, has delivered striking results in studies of people with severe sickle cell disease. In its main clinical trial, most patients who could be assessed had no severe vaso-occlusive events — the painful crises that are a hallmark of the disease — during the planned follow-up period. Patients also showed large increases in fetal hemoglobin, a form of hemoglobin that can reduce sickling of red blood cells (see Figure 1). The short-term benefit appears unusually large for patients who have repeated severe crises 1.

The U.S. Food and Drug Administration has approved Casgevy for people aged 12 and older who have recurrent vaso-occlusive crises. Follow-up reports suggest that the clinical gains and hemoglobin improvements have continued after treatment, though the available evidence does not yet show what will happen over a lifetime.

The benefits may reach beyond fewer hospital visits. Patients in the exa-cel program reported improvements in pain and in broader measures of health-related quality of life. That matters because sickle cell disease can shape nearly every part of daily life, from work and school to sleep, mobility and mental health. For people who respond, the treatment may improve both health and day-to-day wellbeing 2.

CRISPR therapy also avoids one major obstacle to bone-marrow transplantation: finding a compatible donor. Casgevy uses a patient’s own stem cells, which are edited in a laboratory and returned to the body. That means no matched donor is needed, and it avoids graft-versus-host disease, a serious complication in which donated cells attack the patient’s body 3.

The treatment is expensive, but some economic models suggest a one-time therapy could still represent good value if it produces lasting health gains. That conclusion depends heavily on its price, how long its benefits endure, who can receive it and whether access is distributed fairly 4.

The case against

The central problem with making CRISPR therapy a standard treatment for all patients is that the evidence, although encouraging, is not yet broad or mature enough. The key Casgevy trial did not randomly compare treated patients with people receiving the best existing care. It was a single-arm study involving a relatively small and selected group of patients, and follow-up remains limited (see Figure 2). Researchers cannot yet say with confidence that it is better than optimized alternatives for every patient 5.

Existing treatments have not been displaced. Hydroxyurea can reduce pain crises and other complications, while donor stem-cell transplantation can cure some patients who have an appropriate donor. CRISPR therapy may be particularly valuable for people with severe recurring crises when conventional treatment is not enough or is not acceptable, but its advantage is less clear for people with milder disease.

Nor is Casgevy a simple outpatient procedure. Patients must undergo stem-cell collection, intensive chemotherapy-like conditioning to clear space in the bone marrow, and reinfusion of the edited cells. The process can bring severe low blood counts, infections, liver toxicity and risks to fertility, including ovarian failure. A treatment whose expected benefits outweigh its risks in severe disease may not have the same balance for patients with fewer complications, other health conditions or fertility concerns 6.

The long-term picture is also incomplete. Because the therapy permanently alters stem cells, researchers must watch for rare delayed harms, loss of benefit over time, unintended genetic changes or abnormal cell growth. Regulators require long-term monitoring, and current follow-up is encouraging but cannot prove lifelong disease correction or rule out very late side effects 7.

Finally, broad adoption could deepen existing gaps in care. The therapy requires specialized manufacturing, transplant-capable hospitals, inpatient treatment and prolonged follow-up. High prices, insurance coverage, geography and limited center capacity could all restrict access. In countries where even basic sickle cell services remain incomplete, universal use would require major new infrastructure (see Figure 3) 8.

The bottom line

CRISPR therapy should not yet be adopted as a universal standard treatment for all people with sickle cell disease. The evidence strongly supports it as a major, potentially practice-changing option for eligible patients — especially those aged 12 and older with recurrent severe pain crises who can be treated at experienced centers.

Decisions should remain individualized, taking account of disease severity, response to existing treatment, transplant options, fertility priorities, organ health, patient preferences and practical access. The biggest unanswered question is whether long-term comparative studies will show that CRISPR therapy delivers greater lifetime benefit and acceptable safety than the best current care across the full range of patients and health systems.